Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$34.49 USD
+0.46 (1.35%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $34.50 +0.01 (0.03%) 6:04 PM ET
3-Hold of 5 3
C Value D Growth D Momentum F VGM
Structure Therapeutics Inc. Sponsored ADR (GPCR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$84.56 | $100.00 | $65.00 | 148.49% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Structure Therapeutics Inc. Sponsored ADR comes to $84.56. The forecasts range from a low of $65.00 to a high of $100.00. The average price target represents an increase of 148.49% from the last closing price of $34.03.
Analyst Price Targets (9 )
Broker Rating
Structure Therapeutics Inc. Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/7/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
6/3/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
5/9/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/9/2024 | Cantor Fitzgerald & Co | Prakhar Agrawal | Not Available | Strong Buy |
3/8/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
2/27/2024 | LifeSci Capital | Myriam Belghiti | Not Available | Strong Buy |
10/2/2023 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $84.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.23 |